BUSINESS● LOW3h ago · Sep 4, 2026, 4:01 PM
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
Yahoo Finance · global
Teva backed a bid of up to $125 million in cash plus assumed liabilities for BioXcel's assets, raising questions about whether the bankruptcy-sale risk is justified by the potential at-home market opportunity. This signals a strategic move in the pharmaceutical sector with financial implications.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS12m agoCatalyst watch: Apple's high-stakes iPhone event, Oracle, CPI, and the NFL returnsSeeking Alpha TechBUSINESS46m agoWomen accounted for almost all of job gains in August. Here's whyCNBCBUSINESS48m agoBauxite transformation: how Guinea wants to impose its refineriesJeune AfriqueBUSINESS52m agoVizag MP Sribharat hopeful of turnaround in VSP fortuneThe Hindu